{
  "id": "602823e61cb411341a0000f9",
  "type": "list",
  "question": "Which drugs are included in the IROX regimen for colorectal cancer?",
  "ideal_answer": "IROX regimen for colorectal cancer includes irinotecan and oxaliplatin.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/17687151",
    "http://www.ncbi.nlm.nih.gov/pubmed/25349295",
    "http://www.ncbi.nlm.nih.gov/pubmed/18824706",
    "http://www.ncbi.nlm.nih.gov/pubmed/19822515",
    "http://www.ncbi.nlm.nih.gov/pubmed/14665611",
    "http://www.ncbi.nlm.nih.gov/pubmed/29211295",
    "http://www.ncbi.nlm.nih.gov/pubmed/17901952",
    "http://www.ncbi.nlm.nih.gov/pubmed/29246011",
    "http://www.ncbi.nlm.nih.gov/pubmed/15677624",
    "http://www.ncbi.nlm.nih.gov/pubmed/17559146",
    "http://www.ncbi.nlm.nih.gov/pubmed/19390546",
    "http://www.ncbi.nlm.nih.gov/pubmed/19001325",
    "http://www.ncbi.nlm.nih.gov/pubmed/20530282",
    "http://www.ncbi.nlm.nih.gov/pubmed/19444385"
  ],
  "snippets": [
    {
      "text": "BACKGROUND: The authors hypothesized that patients with metastatic colorectal cancer (mCRC) who had tumors with low thymidylate synthase (TS-L) expression would have a higher response rate to combined 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) plus bevacizumab (FOLFOX/Bev) than those with high TS (TS-H) expression and that combined irinotecan and oxaliplatin (IROX) plus bevacizumab (IROX/Bev) would be more effective than FOLFOX/Bev in those with TS-H tumors.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29211295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The 10 regimens included folinic acid + 5-fluorouracil + oxaliplatin (FOLFOX), folinic acid + 5-fluorouracil + irinotecan (FOLFIRI), folinic acid + 5-fluorouracil + gemcitabine (FFG), folinic acid + 5-fluorouracil + trimetrexate (FFT), folinic acid + 5-fluorouracil (FF), irinotecan + oxaliplatin (IROX), raltitrexed + oxaliplatin (TOMOX), folinic acid + tegafur-uracil (FTU), raltitrexed, and capecitabine. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29246011",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We simulated phase II trials by resampling patients from N9741, a randomized phase III trial of chemotherapy regimens for metastatic colorectal cancer, and compared the power of various end points to detect the superior therapy (FOLFOX [infusional fluorouracil, leucovorin, and oxaliplatin] had longer overall survival than both IROX [irinotecan plus oxaliplatin] and IFL [irinotecan and bolus fluorouracil plus leucovorin]).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25349295",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PATIENTS AND METHODS: Germline DNA was extracted from 520 patients on the North American Gastrointestinal Intergroup N9741 study. Three study arms were evaluated: IFL (fluorouracil [FU] + irinotecan [IRN]), FOLFOX (FU + oxaliplatin), and IROX (IRN + oxaliplatin).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20530282",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The patient had progression of disease on IROX (irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine/capecitabine and developed HFS again, which was controlled with aggressive skin care and vitamin B6 treatment.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19822515",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Haller et al. demonstrated that irinotecan plus oxaliplatin (IROX) is more efficacious than irinotecan alone after fluoropyrimidine failure in advanced colorectal cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19390546",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "UNLABELLED: PURPOSE To determine whether irinotecan plus oxaliplatin (IROX) is superior to irinotecan alone in patients with metastatic colorectal cancer (CRC) previously treated with single-agent fluoropyrimidines. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18824706",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The 10 regimens included folinic acid + 5-fluorouracil + oxaliplatin (FOLFOX), folinic acid + 5-fluorouracil + irinotecan (FOLFIRI), folinic acid + 5-fluorouracil + gemcitabine (FFG), folinic acid + 5-fluorouracil + trimetrexate (FFT), folinic acid + 5-fluorouracil (FF), irinotecan + oxaliplatin (IROX), raltitrexed + oxaliplatin (TOMOX), folinic acid + tegafur-uracil (FTU), raltitrexed, and capecitabine.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29246011",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Updated efficacy and toxicity analysis of irinotecan and oxaliplatin (IROX) : intergroup trial N9741 in first-line treatment of metastatic colorectal cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17559146",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "We attempted to evaluate the efficacy and safety of a combination of irinotecan and oxaliplatin (IROX) as a salvage treatment for patients with gemcitabine- and 5-FU- refractory pancreatic cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19444385",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "isease on IROX (irinotecan/oxaliplatin) and irinotecan/cetuximab regimens. He was started on gemcitabine/ca",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19822515",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "RESULTS: The observed 5-year survival with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX) of 9.8% was better than with irinotecan plus bolus fluorouracil and leucovorin (IFL; 3.7%; P = .04) or with bolus irinotecan/oxaliplatin (IROX; 5.1%; P = .128).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19001325",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We evaluated the irinotecan-oxaliplatin combination (IROX regimen) in previously untreated patients with non-favorable subsets of unknown primary carcinomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17901952",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PATIENTS AND METHODS: Patients were concurrently randomly assigned to receive irinotecan and bolus fluorouracil plus leucovorin (IFL, control combination), oxaliplatin and infused fluorouracil plus leucovorin (FOLFOX), or irinotecan and oxaliplatin (IROX).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/14665611",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Pilot study of irinotecan/oxalipltin (IROX) combination chemotherapy for patients with gemcitabine- and 5-fluorouracil- refractory pancreatic cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19444385",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": " The three treatment arms consist of IFL (irinotecan + FU/LV), FOLFOX4 (oxaliplatin + FU/LV), and IROX (irinotecan + oxaliplatin).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/17687151",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PATIENTS AND METHODS: Patient research records in study arms (A) irinotecan/5-FU/leucovorin (LV) (IFL, n = 264), (F) oxaliplatin/5-FU/LV (FOLFOX4, n = 267) and (G) oxaliplatin/irinotecan (IROX, n = 265) were reviewed. TTP and median OS were calculated",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/15677624",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "irinotecan, oxaliplatin"
}